✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Rivoglitazone is an investigational drug.
There have been 5 clinical trials for Rivoglitazone. The most recent clinical trial was a Phase 3 trial, which was initiated on November 14th 2007.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and [disabled in preview]. The leading clinical trial sponsors are Daiichi Sankyo Inc., Daiichi Sankyo, Inc., and Daiichi Sankyo Co., Ltd.
Recent Clinical Trials for Rivoglitazone
|Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus||Daiichi Sankyo Inc.||Phase 3|
|Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus||Daiichi Sankyo, Inc.||Phase 3|
|Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes||Daiichi Sankyo Co., Ltd.||Phase 2|